Your browser doesn't support javascript.
loading
Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.
Faluyi, Olusola O; Eng, Lawson; Qiu, Xin; Che, Jiahua; Zhang, Qihuang; Cheng, Dangxiao; Ying, Nanjiao; Tse, Alvina; Kuang, Qin; Dodbiba, Lorin; Renouf, Daniel J; Marsh, Sharon; Savas, Sevtap; Mackay, Helen J; Knox, Jennifer J; Darling, Gail E; Wong, Rebecca K S; Xu, Wei; Azad, Abul Kalam; Liu, Geoffrey.
Afiliação
  • Faluyi OO; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Eng L; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Qiu X; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Che J; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Zhang Q; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Cheng D; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Ying N; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Tse A; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Kuang Q; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Dodbiba L; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Renouf DJ; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Marsh S; Institute of Biomedical Engineering, Hangzhou Dianzi University, Zhejiang, China.
  • Savas S; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Mackay HJ; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Knox JJ; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Darling GE; British Columbia Cancer Agency, Department of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Wong RK; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
  • Xu W; Discipline of Genetics, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
  • Azad AK; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Liu G; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Cancer Med ; 6(2): 361-373, 2017 02.
Article em En | MEDLINE | ID: mdl-28074552

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma / Polimorfismo de Nucleotídeo Único / MicroRNAs / Redes Reguladoras de Genes Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma / Polimorfismo de Nucleotídeo Único / MicroRNAs / Redes Reguladoras de Genes Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article